Telomerase targeting by retinoids in cells from patients with myeloid leukemias of various subtypes, not only APL

Leukemia

Volumn 20, Issue 4, 2006, Pages 599-603

  Pendino, F ^a   Hillion, J ^a   Dudognon, C ^a   Delaunay, J ^b   Mourah, S ^a   Podgorniak, M P ^a   Lafon, I ^c   Chomienne, C ^a   Lanotte, M ^a   Dombret, H ^a   Rousselot, P ^a,d   Segal Bendirdjian E ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

ATRA; Leukemia; Retinoids; Telomerase

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; CD 3640; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER INHIBITION; CLINICAL ARTICLE; DRUG TARGETING; ENZYME INHIBITION; ENZYME REPRESSION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LONG TERM CARE; MALE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TELOMERE;

EID: 33646477843     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404127     Document Type: Article

References (22)

1. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 9082-9086.
2. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-2320.
3. Greenwood MJ, Lansdorp PM. Telomeres, telomerase, and hematopoietic stem cell biology. Arch Med Res 2003; 34: 489-495.
4. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB et al. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clin Cancer Res 1996; 2: 799-803.
5. Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Res 2000; 60: 610-617.
6. Li G, Song YH, Qian LS, Ma XT, Wu KF. Telomerase: Obviously activated in the accelerated phase of chronic myeloid leukemia. Haematologica 2000; 85: 1222-1224.
7. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680-687.
8. Roth A, Vercauteren S, Sutherland HJ, Lansdorp PM. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003; 17: 2410-2417.
9. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54: 3557-3560.
10. Sieglova Z, Zilovcova S, Cermak J, Rihova H, Brezinova D, Dvorackova R et al. Dynamics of telomere erosion and its association with genome instability in myelodysplasic syndromes (MDS) and acute myelogenous leukemia arising from MDS: A marker of disease prognosis? Leuk Res 2004; 28: 1013-1021.
11. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E. Natural and pharmacological regulation of telomerase. Nucleic Acids Res 2002; 30: 839-865.
12. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
13. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results Blood 1990; 76: 1704-1709.
14. Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: Implications for clinical management of the disease. Blood Rev 2003; 17: 71-97.
15. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Segal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA 2001; 98: 6662-6667.
16. Pendino F, Sahraoui T, Lanotte M, Segal-Bendirdjian E. A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation. Leukemia 2002; 16: 826-832.
17. Pendino F, Dudognon C, Delhommeau F, Sahraoui T, Flexor M, Bennaceur-Griscelli A et al. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death. Oncogene 2003; 22: 9142-9150.
18. Segal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995; 218: 201-212.
19. Xu D, Gruber A, Peterson C, Pisa P. Supression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia 1996; 10: 1354-1357.
20. Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J et al. Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia 2005; 19: 1806-1811.
21. Sumi M, Tauchi T, Sashida G, Nakajima A, Gotoh A, Shin-Ya K et al. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int J Oncol 2004; 24: 1481-1487.
22. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005; 105: 1742-1749.